Is PT-141 safe?

What does the safety evidence cover?

PT-141 is another name for bremelanotide. The largest published trials studied an injection in premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. They did not test the compounded preparation offered through AnthologyRX. Read the phase 3 research.

That distinction matters when someone calls PT-141 “safe.” Ask which product, which patients and which evidence they mean. Your own prescription deserves a more specific answer than a reassuring adjective.

Side effects and screening

The Vyleesi prescribing information identifies these issues:

• Nausea: reported by 40% of treated patients versus 1.3% on placebo in the phase 3 trials. Flushing, injection-site reactions, headache and vomiting also occurred.
• Cardiovascular effects: temporary blood-pressure increases and heart-rate reductions. Vyleesi is contraindicated with uncontrolled hypertension or known cardiovascular disease.
• Skin darkening: pigmentation changes may persist.
• Interactions: slowed stomach emptying can affect oral medicines. Avoid Vyleesi with oral naltrexone used for alcohol or opioid dependence.
• Pregnancy: the label advises effective contraception and stopping Vyleesi if pregnancy is suspected.

Bring your complete medication list, recent blood-pressure information and relevant medical history to the Assessment. Include supplements, recreational substances, pregnancy plans and any previous reaction to treatment. Use the clinician's and dispensing pharmacy's instructions for your specific prescription.

Is compounded PT-141 FDA-approved?

No. The PT-141 injection offered here is compounded, not Vyleesi. Compounded drugs do not receive FDA premarket review for safety, effectiveness or quality. FDA explains the distinction.

Reviewing the molecule's clinical data is one part of evaluating care. Verifying the prescribing clinician, dispensing pharmacy and exact preparation is another. Our guide to evaluating a peptide provider gives you questions and official lookup tools for both.

What about safety for men?

Vyleesi is not indicated for men. A clinician considering compounded PT-141 for a man must assess the evidence and individual risks separately. The women's approval trials cannot settle that question. See what the research in men actually studied.

What happens if I am not approved?

Your clinician explains the decision and, where useful, recommends a next step. If they determine you are not a candidate for any available treatment, any consultation fee paid is refunded within 7–10 business days. If you are approved and a prescription is issued, the consultation fee is non-refundable even if you do not proceed with a subscription. Read the refund policy.